| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience |
| 14 Sep 2026 |
8-K: Other Events
On September 3, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), approved a Director Resignation Policy that requires a director, following certification of the stockholder vote from the meeting at which the el... |
| 25 Aug 2026 |
8-K: Other Events
On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Com... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027 |
| 28 Jul 2026 |
8-K: Other Events
On July 27, 2026, upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. (the “Board”) approved the reorganization of its Nominating and Governance Committee and the Compensation Commit... |
| 17 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., July 17, 2026 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform... |
| 07 Jul 2026 |
8-K: Other Events
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of July 1, 2026, by and among Vaxart, Inc., a Delaware corporation (the “Company”), on the one hand, and Daniel P. Houle, a citizen of the United States, Mark Silv... |
| 26 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort |
| 19 May 2026 |
8-K: Other Events
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 |
| 23 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform |
| 21 Apr 2026 |
8-K: Other Events
On April 20, 2026, Vaxart, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its lease agreement (the “Utah Avenue Lease”) with a landlord (the “Utah Avenue Landlord”) relating to certain properties currently leased to ... |
| 17 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
PURCHASE AGREEMENT (the “Agreement”), dated as of April 16, 2026, by and between VAXART, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 |
| 29 Dec 2025 |
8-K: Termination of a Material Definitive Agreement
On December 18, 2025, Vaxart, Inc., a Delaware corporation (the “Company”), entered into a termination agreement (the “Termination Agreement”) with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership (the “Landlord... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties |
| 05 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Collaboration positioned to leverage Vaxart’s oral vaccine platform and Dynavax’s commercial experience to address the long-term need for easily administered COVID-19 vaccine options |
| 10 Oct 2025 |
8-K: Regulation FD Disclosure
As previously disclosed, on August 5, 2025, Vaxart, Inc. (the “Company”) received written notification (the “Previous Notice”) in the form of a stop work order, directing the Company to stop work on all of the Company’s efforts with resp... |
Loading...